Merck shells out $10 billion for London-based lung therapy firm Verona

Merck announced the acquisition of UK-based Verona Pharma for approximately $10 billion, paying $107 per American depository share, representing a 23% premium. This strategic move aims to strengthen Merck's respiratory treatment portfolio and diversify its revenue base as its top-selling cancer drug, Keytruda, faces patent expiry from 2028. Verona's key asset, Ohtuvayre, an approved inhalable treatment for COPD, generated $42.3 million in annual sales and is projected by analysts to achieve over $3 billion in peak annual sales, providing a significant new growth driver for Merck beyond Keytruda's nearly $30 billion in 2024 sales.

Analysis

Merck is executing a significant strategic acquisition by purchasing Verona Pharma for approximately $10 billion, a move designed to diversify its revenue streams ahead of the 2028 patent expiry of its blockbuster cancer drug, Keytruda, which generated nearly $30 billion in 2024. This deal, representing Merck's largest since its 2023 Prometheus buyout, underscores an aggressive M&A strategy to mitigate reliance on a single product. The acquisition centers on Verona's recently approved COPD treatment, Ohtuvayre, an inhalable, non-steroid drug that complements Merck's existing respiratory portfolio. While Ohtuvayre's initial annual sales are modest at $42.3 million, Jefferies analysts project peak annual sales could exceed $3 billion, offering Merck a substantial long-term growth asset. The offer of $107 per share constitutes a 23% premium to Verona's last closing price, signaling Merck's conviction in Ohtuvayre's market potential and its strategic fit.

Key Decisions for Investors

• For Merck investors, this acquisition should be viewed as a crucial long-term positive, as it directly addresses the significant revenue risk posed by Keytruda's upcoming patent cliff by adding a high-potential asset in a core therapeutic area.
• Verona Pharma shareholders are presented with a compelling exit opportunity at a 23% premium, allowing them to realize significant value immediately and de-risk their investment from the future commercialization challenges of Ohtuvayre.
• Investors should note Merck's continued M&A appetite, suggesting that other mid-cap biotech firms with promising, late-stage assets, particularly in respiratory diseases, may become acquisition targets, potentially driving further consolidation in the sector.